{"id":"W2979372680","doi":"10.1182/blood.v124.21.1701.1701","title":"Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Follicular lymphoma; Tolerability; Chronic lymphocytic leukemia; Bendamustine; Phases of clinical research; Lymphoma; Gastroenterology; Clinical endpoint; Progressive disease; Oncology; Adverse effect; Chemotherapy; Clinical trial; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002972046,0.000172743,0.0004331213,0.000223162,0.00002691188,0.00001063764,0.0001491134,0.00007465057,0.00002107641],"category_scores_gemma":[0.000200777,0.0001309657,0.00003732217,0.000402978,0.00007923376,0.00006113815,0.0001112644,0.0001214295,0.00001560545],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001297909,"about_ca_system_score_gemma":0.001775236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007925541,"about_ca_topic_score_gemma":0.0001558047,"domain_scores_codex":[0.9979736,0.00006136525,0.0003976808,0.0003429147,0.0008733715,0.0003510585],"domain_scores_gemma":[0.9988869,0.0000973173,0.0001099704,0.0005563474,0.0001865776,0.0001628599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.008230306,0.4122101,0.5428438,0.0006324782,0.0005868592,0.0002196397,0.006776683,0.00002751023,0.003178269,0.00005630259,0.0002522972,0.02498572],"study_design_scores_gemma":[0.7924814,0.01957599,0.1775854,0.0003652213,0.000192341,0.00002730585,0.0004497829,0.0005370755,0.008414499,0.000003707527,0.000170304,0.0001969754],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980611,0.00003157594,0.00001920512,0.00001595043,0.00004556887,0.001179758,0.000008667043,0.00002564381,0.0006125888],"genre_scores_gemma":[0.9995571,0.000001814799,0.0001426409,0.00005492408,0.00008380623,0.00005125721,0.00001791691,0.00003395495,0.0000565449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7842511,"threshold_uncertainty_score":0.5340625,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01314186849954683,"score_gpt":0.2788585589699332,"score_spread":0.2657166904703863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}